Hengrui Pharmaceutical (600276.SH): Phorolapitampalonosetron for injection approved for new indications

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target antiemetic injection with phosphorapitamparonosetron for injection. The approved indication is “for the prevention of acute and delayed nausea and vomiting caused by moderate emetic chemotherapy (MEC) in adult patients”.